Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 372

3.

PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.

Petrella BL, Brinckerhoff CE.

Cancer Biol Ther. 2009 Jul;8(14):1389-401. Epub 2009 Jul 30.

4.

TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.

Shang D, Liu Y, Yang P, Chen Y, Tian Y.

Urology. 2012 Apr;79(4):966.e1-7. doi: 10.1016/j.urology.2011.12.011. Epub 2012 Feb 15.

PMID:
22341602
5.

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.

Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S.

Cancer Res. 2005 Jun 15;65(12):5221-30.

6.

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.

Mol Cell Biol. 2005 Jul;25(13):5675-86.

7.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
8.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

9.

Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.

Kong HS, Lee S, Beebe K, Scroggins B, Gupta G, Lee MJ, Jung YJ, Trepel J, Neckers L.

Mol Pharmacol. 2010 Dec;78(6):1072-8. doi: 10.1124/mol.110.066514. Epub 2010 Sep 2.

10.
11.

Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor.

Wacker I, Sachs M, Knaup K, Wiesener M, Weiske J, Huber O, Akçetin Z, Behrens J.

Mol Cell Biol. 2009 Apr;29(7):1707-18. doi: 10.1128/MCB.01184-07. Epub 2009 Jan 21.

12.

Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.

Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma M, Liu K, Yao Y, Huang Q, Zhang Y, Zhang X.

Oncotarget. 2016 Apr 5;7(14):18280-94. doi: 10.18632/oncotarget.7807.

13.

von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.

Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-Suárez S, Temes E, Méndez F, Yánez-Mo M, Ohh M, Landázuri MO.

Cancer Res. 2006 Feb 1;66(3):1553-60.

14.

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S.

J Biol Chem. 2003 Nov 7;278(45):44966-74. Epub 2003 Aug 27.

15.
16.

Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.

Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, Ohh M.

Cell Cycle. 2007 Nov 15;6(22):2810-6. Epub 2007 Aug 29.

PMID:
17998805
17.

Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype.

Mahimkar R, Alfonso-Jaume MA, Cape LM, Dahiya R, Lovett DH.

Carcinogenesis. 2011 Dec;32(12):1806-14. doi: 10.1093/carcin/bgr216. Epub 2011 Sep 28.

18.

Hypoxia promotes HO-8910PM ovarian cancer cell invasion via Snail-mediated MT1-MMP upregulation.

Sun L, Lin P, Qin Z, Liu Y, Deng LL, Lu C.

Exp Biol Med (Maywood). 2015 Nov;240(11):1434-45. doi: 10.1177/1535370215570205. Epub 2015 Feb 13.

19.

ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.

Carew JS, Esquivel JA 2nd, Espitia CM, Schultes CM, Mülbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST.

PLoS One. 2012;7(1):e31120. doi: 10.1371/journal.pone.0031120. Epub 2012 Jan 25.

20.

Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M.

Carcinogenesis. 2007 Mar;28(3):529-36. Epub 2006 Aug 18.

PMID:
16920734

Supplemental Content

Support Center